IBio Total Current Liabilities 2010-2024 | IBIO

IBio total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.

IBio Total Current Liabilities 2010-2024 | IBIO

IBio total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$159.1B
Vertex Pharmaceuticals (VRTX)$124.6B
Bristol Myers Squibb (BMY)$118.6B
Gilead Sciences (GILD)$114.8B
CSL (CSLLY)$88.8B
Regeneron Pharmaceuticals (REGN)$86B
GSK (GSK)$71.3B
Argenex SE (ARGX)$35.6B
Alnylam Pharmaceuticals (ALNY)$33.3B
BioNTech SE (BNTX)$24.8B
Biogen (BIIB)$24B
Illumina (ILMN)$22.6B
BeiGene (BGNE)$18.8B
Moderna (MRNA)$15.3B
Incyte (INCY)$15B
Genmab (GMAB)$14B
Insmed (INSM)$12.7B
BioMarin Pharmaceutical (BMRN)$12.5B
Vaxcyte (PCVX)$11.6B
Bio-Techne Corp (TECH)$11.5B
Sarepta Therapeutics (SRPT)$10.4B
Exelixis (EXEL)$10B
Revolution Medicines (RVMD)$9.7B
QIAGEN (QGEN)$9.6B
Exact Sciences (EXAS)$9.4B
Bio-Rad Laboratories (BIO.B)$9.4B
Intra-Cellular Therapies (ITCI)$9.3B
Roivant Sciences (ROIV)$8.6B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.5B